Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belinostat and Erlotinib in NSCLC
NCT01188707Phase 2Terminated
- Sponsor
- Herlev Hospital
- Start
- Oct 2010
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of belinostat in non-small cell lung cancer (NSCLC), sponsored by Herlev Hospital. Primary endpoint: Safety and Tolerability at 1 year. Started Oct 2010; status: terminated.
02
Drugs
belinostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01188707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01188707.